1. Home
  2. KXIN vs PRPO Comparison

KXIN vs PRPO Comparison

Compare KXIN & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$4.02

Market Cap

4.7M

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$24.02

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
KXIN
PRPO
Founded
2015
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
32.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KXIN
PRPO
Price
$4.02
$24.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.5M
14.5K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,000.00
$22,800,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.95
52 Week Low
$2.94
$3.90
52 Week High
$75.00
$28.50

Technical Indicators

Market Signals
Indicator
KXIN
PRPO
Relative Strength Index (RSI) 60.00 53.44
Support Level $3.32 $24.00
Resistance Level $5.80 $25.62
Average True Range (ATR) 0.93 1.24
MACD 0.08 -0.18
Stochastic Oscillator 67.98 43.43

Price Performance

Historical Comparison
KXIN
PRPO

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: